Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Forge Therapeutics Receives 1st Federal Funding Award to Advance Superbug Program | ||
By: PR Newswire Association LLC. - 26 Jul 2016 | Back to overview list |
|
SAN DIEGO, July 26, 2016 /PRNewswire/ -- Forge Therapeutics, Inc. today announced its 1st funding award from the National Institutes of Health (NIH) to support the advancement of its lead program targeting LpxC for treating drug resistant Gram-negative 'superbugs.' The non-dilutive funding is a Phase I Small Business Innovation Grant (SBIR) awarded by the National Institute of Allergy and Infectious Diseases for the project "Novel Small Molecule Inhibitors of LpxC for Multi-Drug Resistant Gram-Negative Bacteria." "The Federal government has a track record of supporting antibiotic discovery programs and we are pleased to receive our 1st award of non-dilutive funding to advance our ground breaking LpxC program. In addition, we have assembled an advisory team of antibiotic experts having over 130 years of experience and responsible for the development of three innovative antibiotics," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics. "With Federal support and experienced antibiotic advisors on-board, we are well positioned to execute our strategy to develop a desperately needed antibiotic that is effective against Gram-negative superbugs." "It has been over 50 years since the last FDA approval of a novel class of antibiotics targeting Gram-negative bacteria," said Karen Joy Shaw, Ph.D. "Forge's innovative chemistry approach has demonstrated rapid progress resulting in novel compounds with significant potency against Gram-negative bacteria." Forge Therapeutics Antibiotic Key Opinion Team:
About LpxC About Forge Therapeutics, Inc. Contact: Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO
SOURCE Forge Therapeutics, Inc. |
||
|
||
Copyright 2016 PR Newswire Association LLC. | Back to overview list |